Naslov
Portal triad obstruction and reperfusion in rats induced the hemorrhagic congestion in the stomach, duodenum, jejunum, cecum, colon, and esophageal bleeding. Pentadecapeptide BPC 157 counteracts these complications along with portal hypertension

Autori
Kolovrat, Marijan ; Gojković, Slaven ; Krezić, Ivan ; Malekinušić, Dominik ; Drmić, Domagoj ; Barišić, Ivan ; Đuzel, Antonija ; Horvat, Katarina ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gastroenterology (New York, N.Y. 1943), 156 (2019), 6(S) / - , 2019, S-562

Skup
Digestive Disease Week

Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 18.05.2019. - 21.05.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
portal triad obstruction ; reperfusion ; BPC 157

Sažetak
Aim. Pentadecapeptide BPC 157 therapy in temporary portal triad obstruction (PTO) (hepatic artery, portal vein, common bile duct, 30 min in rats), and in reperfusion period thereafter, in post-PTO- period, during 15 min and 24 h. The counteraction of portal hypertension and severe hemorrhagic congestion of the stomach, duodenum, jejunum, cecum, colon, and esophageal bleeding as Pringle maneuver complications. Previously, we noted in rats with PTO that BPC 157 increases vessels branching in the intestinal serosa, counteracts intestinal lesions, counteracts free radical formation and most importantly, counteracts portal hypertension and caval hypotension (Gastroenterology, 2017, Vol. 152, Issue 5, S909– S910 ; 2015, Vol. 148, Issue 4, S-650, 2015, Vol. 148, Issue 4, S-548). Likewise, BPC 157 counteracts the lesions in the whole GI-tract (Curr Pharm Des 2018 ; 24(18):1990-2001). Methods: Medication (BPC 157 (10 μg/kg, 10 ng/kg), or saline (5 ml/kg) (controls)) was applied as a bath at the clamped area immediately after portal triad clamping in rats with PTO or at the area that used to be clamped at 1 min or at 24 h reperfusion time. Results: A period of 30 min of PTO much like reperfusion during 15 min and 24 h regularly produced severe hemorrhagic congestion (scored 0- 4) of the stomach, duodenum, jejunum, cecum, colon, and esophageal bleeding in all controls, along with microscopy findings. Contrarily, given either in ischemia period or in reperfusion period, BPC 157 counteracts severe hemorrhagic congestion in all organs (Fig.1, PTO-period, 30 min, ischemia (upper), post-PTO-period, reperfusion, 15 min (lower), c (control), B (BPC 157)) ; *P≤0.05, at least vs. control), counteracts esophageal bleeding and maintained grossly intact esophageal mucosa(Fisher exact probability test P≤0.05 at least vs. control)). BPC 157 promptly induced effective shunting (venography in portal vein below ligation, portal vein-superior mesenteric veininferior mesenteric vein-rectal veins-left iliac vein-inferior caval vein, (Fig. 2, control (left))), BPC 157 (right), since attenuates portal hypertension (mmHg) in PTO-period (means±SD, 65±5 vs. 20±3 (μg), 22±3 (ng)), and completely eliminates pre-existing portal hypertension in post-PTO-period (55±5 mmHg) resulting in the values much like in the normal rats (the portal pressure between 3-5 mmHg). Conclusion. Pringle maneuver and its consequences may have BPC 157 application as a successful therapy. BPC 157 therapy distinctively mitigates the whole syndrome. It has therapy effect applied in ischemia (PTO-period) much like therapy effect given in reperfusion (post-PTO- period). This involves the counteraction of the course of the hemorrhagic congestion in the stomach, duodenum, jejunum, cecum, colon, and esophageal bleeding, along with prompt counteraction of portal hypertension and adequate shunt rapid formation.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA